

National Board of Examinations

Question Paper Name :	DrNB Clinical Immunology and Rheumatology Paper3
Subject Name :	DrNB Clinical Immunology and Rheumatology Paper3
Creation Date :	2023-10-15 15:58:56
Duration :	180
Share Answer Key With Delivery Engine :	No
Actual Answer Key :	No

DrNB Clinical Immunology and Rheumatology Paper3

Group Number :	1
Group Id :	3271872458
Group Maximum Duration :	0
Group Minimum Duration :	180
Show Attended Group? :	No
Edit Attended Group? :	No
Group Marks :	100
Is this Group for Examiner? :	No
Examiner permission :	Cant View
Show Progress Bar? :	No

DrNB Clinical Immunology and Rheumatology Paper3

Section Id :	3271872461
Section Number :	1

Section type :	Offline
Mandatory or Optional :	Mandatory
Number of Questions to be attempted :	10
Section Marks :	100
Enable Mark as Answered Mark for Review and Clear Response :	Yes
Maximum Instruction Time :	0
Sub-Section Number :	1
Sub-Section Id :	3271872465
Question Shuffling Allowed :	No
Is Section Default? :	null

Question Number : 1 Question Id : 32718724813 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

Please write your answers in the answer booklet within the allotted pages as follows:-

Question Number	Answer to be attempted within	Question Number	Answer to be attempted within
Q. 1	Page 1-5	Q. 6	Page 26-30
Q. 2	Page 6-10	Q. 7	Page 31-35
Q. 3	Page 11-15	Q. 8	Page 36-40
Q. 4	Page 16-20	Q. 9	Page 41-45
Q. 5	Page 21-25	Q. 10	Page 46-50

1. a) Discuss the clinical features and classification criteria of MAS secondary to autoimmune rheumatic diseases. [5]

b) Discuss newer therapies for MAS secondary to juvenile and adult autoimmune diseases. [5]

Question Number : 2 Question Id : 32718724814 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Mention the clinical subtypes of giant cell arteritis (GCA)–polymyalgia rheumatica (PMR)

spectrum disease (GPSD). [2]

b) Write briefly on clinical, laboratory and imaging wise risk stratification of GPSD. [4]

c) Discuss the points of differentiation between giant cell arteritis and Takayasu arteritis. [4]

Question Number : 3 Question Id : 32718724815 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Mention the categories of devices used to protect and stabilize the joint in patients with inflammatory arthritis with one example each. [3]

b) Describe the various modalities of physical intervention for acute, subacute and chronic stages of active inflammatory arthritis. [7]

Question Number : 4 Question Id : 32718724816 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Mention the risk factors for neonatal lupus. [2]

b) Enlist the clinical features of a child with neonatal lupus. [3]

c) Describe the preventive treatment for autoimmune congenital heart block. [5]

Question Number : 5 Question Id : 32718724817 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

a) Mention the categories of system-based classification of monogenic autoinflammatory syndromes with 2 examples each. [6]

b) Discuss the importance of somatic mutations in autoimmune diseases giving an example. [4]

Question Number : 6 Question Id : 32718724818 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction

Time : 0

Correct Marks : 10

- a) Compare and contrast the outcome measures of disease activity in systemic lupus erythematosus. [7]
- b) Discuss TULIP1 and TULIP 2 trials in SLE. [3]

Question Number : 7 Question Id : 32718724819 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Write the types of pulmonary hypertension observed in connective tissue diseases. [2]
- b) Discuss the investigative modalities used to screen a patient with connective tissue disease for PH (CTD- PH). [3]
- c) Discuss the role of immuno-suppressants in the management of CTD- PH. [3]
- d) Enumerate the newer drugs with mechanism of action for the treatment of PH. [2]

Question Number : 8 Question Id : 32718724820 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Discuss the role of STAT4 gene polymorphism in pathogenesis of systemic lupus erythematosus. [3]
- b) What is SLE risk probability index and its performance in diagnosis of SLE. [2]
- c) Describe the new common patterns of injury described in SLE. [2]
- d) Discuss the role of SGLT-2 inhibitors in management of patients with Lupus. [3]

Question Number : 9 Question Id : 32718724821 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Describe the clinical features of carcinomatous polyarthritis. [3]
- b) What are the positive and negative predictors of malignancy in inflammatory myositis. [4]

c) Discuss the risk of various malignancies in Rheumatoid arthritis. [3]

Question Number : 10 Question Id : 32718724822 Question Type : SUBJECTIVE Consider As Subjective : Yes Calculator : None Response Time : N.A Think Time : N.A Minimum Instruction Time : 0

Correct Marks : 10

- a) Describe the components of microvascular antiphospholipid syndrome (APS). [4]
- b) Write briefly on the role of immuno-suppression in various manifestations of APS. [3]
- c) Describe briefly on role of direct oral anti-coagulants in the management of thrombotic APS. [3]